Czubkowski P, Jankowska I, Pawlowska J

Language: English
References: 17
Page: 550-552
PDF size: 76.98 Kb.

ABSTRACT

Progressive familial intrahepatic cholestasis type 2 (PFIC 2) results from mutations in ABCB11 gene coding bile salt export pump (BSEP). Medical treatment is usually unsuccessful and surgery intervention is necessary. Partial external biliary diversion (PEBD) is regarded as the first choice of surgical treatment. Ileal exclusion (IE) is an alternative operation if external stoma is not tolerated; however, a favorable outcome is uncertain. In chronic liver diseases pregnancy brings additional risk of deterioration of liver function and generally is not recommended. We present the first case report of successful pregnancy in a genetically confirmed PFIC 2 patient after surgical conversion from PEBD to IE.

REFERENCES

1. Pawlikowska L, Strautnieks S, Jankowska I, Czubkowski P, Emerick K, Antoniou A, Wanty, C, et al. Differences in presentation and progression between severe FIC1 and BSEP deficiencies. J Hepatol 2010; 53: 170-8.

2. Kubitz R, Dröge C, Stindt J, Weissenberger K, Häussinger D. The bile salt export pump (BSEP) in health and disease. Clin Res Hepatol Gastroenterol 2012; 36: 536-53.

3. Arnell H, Papadogiannakis N, Zemack H, Knisely AS, Németh A, Fischler B. Follow-up in children with progressive familial intrahepatic cholestasis after partial external biliary diversion. J Pediatr Gastroenterol Nutr 2010; 51: 494-99.

4. Whitington PF, Whitngton GL. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 1988; 95: 130-6.

5. Jankowska I, Czubkowski P, Kalicinski P, Ismail H, Kowalski A, Ryzko J, Pawlowska J. Ileal exclusion in children with progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2014; 58: 92-5.

6. Hollands CM, Rivera-Pedrogo FJ, Gonzalez-Vallina R, Loretde- Mola O, Nahmad M, Burnweit CA. Ileal exclusion for Byler’s Disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 1998; 33: 220-4.

7. Branger B, Ribard D, Tailland ML, Zabadani B. Apheresis for Byler syndrome in pregnancy: Tolerance and effectiveness. Ann Med Interne (Paris) 1999; 150: 70-2.

8. Mathias A, Wax JR, Pinette MG, Cartin A, Blackstone J. Progressive familial intrahepatic cholestasis complicating pregnancy. J Matern Fetal Neonatal Med 2009; 22: 816-19.

9. Cash WJ, Knisely AS, Waterhouse C, Iqbal M, Stokes V, Byrne B, McCormick, PA. Successful pregnancy after liver transplantation in progressive familial intrahepatic cholestasis, type 1. Pediatr Transplant 2011; 15: E174-76.

10. Vallejo M, Briz O, Serrano MA, Monte MJ, Marin J. Potential role of trans-inhibition of the bile salt export pump by protesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol 2006; 44: 1150-7.

11. Arrese M, Reyes H. Intrahepatic cholestasis of pregnancy: a past and present riddle. Ann Hepatol 2006; 5: 202-5.

12. Hay JE. Liver disease in pregnancy. Hepatology 2008; 47: 1067-76.

13. Dixon PH, van Mil SW, Chambers J, Strautnieks S, Thompson RJ, Lammert F, Kubitz R, et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 2009; 58: 537-44.

14. Arrese M. Cholestasis during pregnancy: rare hepatic diseases unmasked by pregnancy. Ann Hepatol 2006; 5: 216-8.

15. Reyes H. Intrahepatic cholestasis of pregnancy and the risk of subsequent hepatobiliary disorders. Hepatology 2014; 60(4): 1451-2.

16. Naoi S, Hayashi H, Inoue T, Tanikawa K, Igarashi K, Nagasaka H, Kage M, et al. Improved liver function and relieved pruritus after 4-phenylbutyrate therapy in a patient with progressive familial intrahepatic cholestasis type 2. J Pediatr 2014; 164: 1219-27.

17. Gonzales E, Grosse B, Cassio D, Davit-Spraul A, Fabre M, Jacquemin E. Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2. J Hepatol 2012; 57: 695-8.